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1. Introduction 
Lymphedema is the accumulation of interstitial fluid within tissues due to the impairment 
of lymphatic function. Dysfunction can result from direct obstruction of lymphatic vessels, 
absence of lymphatic vessels, or inadequate lymphatic function. From congenital forms of 
lymphedema, such as Milroy disease, to acquired forms of lymphedema, such as filiarisis 
lymphedema or post-surgical lymphedema, lymphatic dysfunction contributes significantly 
to the world’s human disease burden. 
Due to the inherent difficulties in visualizing lymphatic channels, research in the 
pathogenesis and treatment of lymphedema has lagged behind similar investigations in 
vascular pathology. Over the past two decades, aggressive research efforts have vastly 
improved our understanding of the lymphatic system, but significant advances in medical 
therapies for lymphedema and lymphatic regeneration are still lacking. To date, the 
majority of treatment strategies for lymphedema (compression stockings, massage, and 
exercise) do not address the underlying molecular pathophysiology (Nakamura & 
Rockson, 2008). 
Several nonspecific pharmacological agents, such as selenium and benzo-pyrones, have 
been studied with limited success. A review of ten different trials of pharmacological 
therapies for lymphedema by Kligman et al. concluded that  insufficient evidence exists to 
support the use of these nonspecific medical therapies at the moment (Kligman et al., 
2004). 
With improvements in our understanding of the molecular mechanisms of lymphedema 
and lymphangiogenesis, however, an increasing number of potential pharmacological 
targets for specific therapies are being identified. Due to ongoing efforts by numerous 
researchers in the study of therapeutic lymphatic regeneration, significant progress is 
being made towards targeted pharmacological therapies for lymphedema. Specific 
molecules that have shown the most promise as therapeutic targets include the vascular 
endothelial growth factors (VEGFs) and their receptors (VEGFRs), cyclooxygenase 2 
(COX-2) selective inhibitors, tumor necrosis factor (TNF)-┙, and transforming growth 
factor (TGF)-┚. 
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2. Nonspecific treatments 
To date, studies have been unable to confirm the effectiveness of nonspecific treatment 
strategies such as selenium and benzo-pyrones on lymphedema, despite their common use 
in clinical practice. Selenium is a drug that is used to prevent or minimize the adverse effects 
of radiotherapy, chemotherapy, or surgery in oncology patients; however, after rigorous 
testing of this therapy, Dennert and Horneber concluded that inadequate evidence exists to  
advocate for or against the use of selenium for lymphedema (Dennert & Horneber, 2006). 
Similarly, benzo-pyrones have been considered a plausible treatment strategy for 
lymphedema, as these molecules reduce vascular permeability and thereby, reduce 
subcutaneous fluid. Furthermore, benzo-pyrones also increase macrophage activity and 
encourage protein degradation, which, in turn, reduces the formation of fibrotic tissue in the 
lymphedematous limb. A recent review of 15 trials of benzo-pyrones in the treatment 
lymphedema, however, failed to uncover any conclusions due to the poor quality of the 
analyzed trials (Badger et al., 2004). The limited and questionable efficacy of current 
nonspecific treatments has led many researchers toward using molecular strategies for the 
development of newer targeted pharmacological therapies. Specific attention has been paid 
to factors responsible for lymphangiogenesis, such as VEGF-C. By stimulating 
lymphangiogenesis and regeneration of lost or damaged lymphatics, VEGF-C offers 
significant promise as a treatment for all-cause lymphedema. 
3. Targeted therapies 
Currently, a number of molecular strategies for the treatment of lymphedema are being 
studied in animal models. Promising results have been obtained in the treatment of mouse 
models of lymphedema via methods of promoting lymphangiogenesis; however, significant 
work is still required before clinical application of these therapies becomes a reality. 
3.1 Treatment with VEGF-C 
In particular, VEGF-C has been found to be a potent regulator of lymphangiogenesis 
through its actions on two receptor tyrosine kinases, VEGFR-2 and VEGFR-3 (Haiko et al., 
2008; Tammela et al., 2011). Multiple studies have evaluated the efficacy of VEGF-C gene 
therapy and plasmid transfection and revealed surprising success in a variety of animal 
lymphedema models. 
The first study to document improvement in the clinical and pathologic features of 
lymphedema by therapeutic enhancement of lymphatic drainage with human VEGF-C gene 
therapy was performed in 2003 by Yoon et al. In two animal models, a rabbit ear model and 
a mouse tail model, these authors treated lymphedema with naked plasmid DNA that 
encoded human VEGF-C (phVEGF-C) injected subcutaneously. Following treatment, 
improvements in both lymphedema and lymphatic function were noted (Yoon et al., 2003). 
Cheung et al. similarly found improvement in surgically-induced lymphedema in a mouse 
tail model using recombinant human VEGF-C. Mice were treated with cautery ablation of 
the large collecting lymphatics of the tail after identification of the vessels with injected 
methylene blue. A lymphedematous state was then documented by evidence of dilated 
cutaneous lymphatics, acute inflammation and hypercellularity, and impairment of immune 
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trafficking via in vivo bioluminescent imaging. Three days post-surgery, the animals were 
then treated with parenteral recombinant human VEGF-C generated from engineered DNA 
encoding the human VEGF homology domain (amino acid residues Thr103-Arg227) fused to 
a human CD33 signal peptide at the N-terminus and a 10x-histidine tag at the C-terminus. 
Upon examination, treated animals were found to have reversal of the lymphedematous 
state to the normal state with resolution of edema, hypercellularity, inflammatory changes, 
and microlymphatic dilation. Both lymphatic vessel number and cross-sectional area were 
reduced following exogenous administration of the recombinant VEGF-C (Cheung et al., 
2006). 
In another mouse model of chronic obstructive lymphedema, treatment with VEGF-C also 
improved lymphedema in the studied animals. The authors injected a pcDNA3.1-VEGF-C 
plasmid into the tail of these mice. Subsequent overexpression of VEGF-C enhanced 
lymphangiogenesis in vivo and improved lymphedema (Hu et al., 2008). 
Using a rat hind limb model of lymphedema, Liu et al. also observed significant 
improvement in lymphedema following focal transfection with VEGF-C DNA. Rats were 
treated with a plasmid DNA encoding human VEGF-C (pcDNA3.1-VEGF-C) and monitored 
for resolution of their surgically-induced lymphedema in comparison to controls. 
Lymphedema was quantitatively reduced at 2 and 4 weeks in the therapy group as 
documented by magnetic resonance imaging (MRI), B-scan ultrasound, and water 
displacement volumetry measurements. Furthermore, numerous newly formed lymphatic 
vessels were observed in treated mice on both histological and immunofluorescence analysis 
(Liu et al., 2008). 
Finally, Tammela et al. found a significant role for adenovirally-delivered VEGF-C in 
improving outcomes of lymph node dissection and transplantation in mice. In their study, 
lymph node dissection and transplantation in combination with adenovirally-delivered 
VEGF-C induced the formation of functional collecting lymphatic vessels and the 
reconstitution of a functional immunological barrier (Tammela et al., 2007). 
3.2 Caveats to VEGF-C Therapies 
Despite the growing body of evidence in support of the efficacy of VEGF-C gene therapy, 
the exact mechanism by which VEGF-C-induced lymphangiogenesis facilitates resolution of 
lymphedema remains controversial. In an effort to elucidate the mechanisms by which 
VEGF-C induces lymphatic microvascular remodeling, Jin et al. examined the effects of anti-
VEGFR-3 neutralizing antibodies in a mouse tail model of post-surgical lymphedema. This 
study demonstrated that VEGFR-3 plays a central mechanistic role in lymphedema 
remodeling. In the presence of the neutralizing antibody, lymphatic remodeling was greatly 
attenuated due to blockage of VEGF-C-induced signaling (Jin da et al., 2009). 
In contrast, Uzarski et al. failed to observe inhibition of edema resolution across surgically-
induced wounds in a mouse tail lymphedema model upon blockage of VEGFR-3. In their 
study, two mouse models were compared. In the first mouse model, scar-free lymphatic 
obstruction was simulated with dissection and removal of the superficial lymphatics from a 
mouse tail. Distal lymphedema was noted, and resolution was stimulated by VEGF-C. 
Edema resolution was not, however, inhibited by VEGFR-3 neutralizing antibodies, 
although lymphangiogenesis was reduced. In the second mouse model, scar-containing 
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lymphatic obstruction was simulated with dissection and removal of the superficial 
lymphatics with cautery. Subsequent treatment with either VEGF-C or VEGFR-3 
neutralizing antibodies resulted in no improvement in lymphedema. The authors concluded 
that interstitial flow dynamics and lymphedema may actually be more dependent on the 
extracellular matrix that reforms at the site of the injury than on lymphangiogenesis and that 
this effect may be impeded by the formation of scar tissue (Uzarski et al., 2008). 
Following the finding that resolution of lymphedema may be more dependent on interstitial 
flow than on VEGFR-3 or VEGF-C, Ongstad et al. set out to clarify the role of VEGFR 
signaling during edema resolution and to probe the mechanism by which VEGF-C hastens 
resolution of edema. In their study, inhibition of VEGFR-3 or VEGFR-2 alone in mouse 
models did not significantly change the evolution of lymphedema relative to controls; 
however, inhibition of both VEGFR-2 and VEGFR-3 led to reduced tissue repair and 
reduced resolution of tail swelling at 40 and 50 days post surgery. Thus, tissue repair was 
crucial to the resolution of edema as this process provides a matrix bridge for fluid drainage. 
These authors then hypothesized that edema resolution in the mouse may be VEGFR 
signaling dependent, but lymphangiogenesis independent (Ongstad et al.). 
Careful analysis by Jin et al. identified 120 mouse genes, many of which share homology 
with human genes, that are upregulated in the presence of lymphedema and normalized 
following therapeutic VEGF-C administration. Many of these genes were found to be 
involved in processes unrelated to lymphangiogenesis, suggesting an underlying, but 
incompletely understood, complexity to VEGF-C-induced lymphedema resolution. It is 
likely that numerous processes, including inflammation, immune response, wound healing, 
angiogenesis, oxidative stress response, and adipogenesis, play important roles in the 
pathogenesis and therapeutic resolution of the disease (Jin da et al., 2009). Additional 
research in this area is certainly warranted. 
3.3 VEGF-C and stem cell combined therapies 
Several recent studies further complicated our understanding of the role of VEGF-C and the 
optimal application of VEGF-C therapy in the treatment of lymphedema. In two papers, 
augmentation strategies using synthetic extracellular matrix material, such as gelatin and/or 
stem cells, co-administered with VEGF-C resulted in greater resolution of lymphedema 
compared to VEGF-C therapy alone. This further highlights the complexity of lymphedema 
and VEGF-C therapy.  
Gelatin is a natural and abundant polymer used for tissue engineering. Gelatin-based 
hydrogels are biodegradable, non-immunogenic, and non-toxic and are able to mimic the 
properties of the extracellular matrix. This polymer can be used to distribute growth factors 
in a localized, sustained, controlled manner to obtain an effective dose response. Due to 
these properties and the success of VEGF-C treatment in lymphedema mouse models, 
Hwang et al. created a mouse hind limb model of lymphedema and applied a gelatin 
hydrogel system to the site of injury to obtain a controlled release of VEGF-C in combination 
with injection of human adipose-derived stem cells (hADSCs). Decreased dermal edema 
depth and increased lymphatic vessel density were observed at all time periods in the mice 
treated with both hydrogel and hADSCs as compared to mice treated with either hydrogel 
or hADSCs alone (Hwang et al.) 
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Similarly, Zhou et al. treated rabbits with hind limb lymphedema using bone marrow 
stromal cells and/or VEGF-C. The rabbits that were treated with both stem cells and the 
growth factor exhibited a significant decrease in volume of edema in the limb as compared 
to rabbits treated with only one of the two agents. Vessel numbers increased in the dual 
treatment group, and VEGF-C expression was also higher in the dual therapy-treated 
animals. The authors concluded that the treatments enhanced the therapeutic effect of each 
other (Hu et al.). Therefore, stem cells may play a role in matrix remodeling and 
lymphangiogenesis, particularly in the setting of upregulated VEGF-C expression; however, 
further research is needed before concrete conclusions can be made. 
3.4 Alternative therapies 
As our understanding of lymphatics has improved, additional therapies with effects on 
lymphangiogenesis have also been identified. One such therapy is extracorporeal shock 
wave therapy (ECT). ECT is used for the treatment of plantar fasciitis and tennis elbow. 
Repeated shock waves are localized to an area to produce neo-vascularization. This 
treatment effectively induces therapeutic angiogenesis and improves myocardial ischemia 
in pigs and humans as well as hind limb ischemia in rabbits via a mechanism involving 
upregulation of VEGF. Serizawa et al. created a rat tail model of lymphedema and 
subsequently subjected the animals to serial ECT therapy.  Enhanced drainage of lymphatic 
fluid as well as upregulation of VEGF-C expression were found in the treatment group 
compared to the controls (Serizawa et al.). 
Similarly, skin graft repairs to injuries in a mouse tail model have also been shown to 
stimulate lymphatic regeneration. In a recent study by Yan et al., ingrowth of lymphatic 
vessels and spontaneous re-connection of existing lymphatics associated with VEGF-C up-
regulation was observed following skin grafting (Avraham et al.). In the future, a 
combination of such therapeutic strategies may be required for optimal management of 
lymphedema. 
3.5 Additional molecular targets 
Clearly, VEGF-C plays an important role in the lymphatic system; however, it is also 
becoming increasingly clear that additional factors are involved in lymphedema. One such 
factor, hepatocyte growth factor (HGF), has been found to promote lymphatic vessel 
formation in mice. Furthermore, both HGF and its high affinity HGF receptor (MET) have 
recently been found to be expressed in lymphatic endothelial cells but not in blood 
endothelial cells. Finegold et al. examined these genes in women with secondary 
lymphedema following treatment for breast cancer and found that patients with both 
primary and secondary lymphedema had mutations in HGF/MET, suggesting that 
mutations in HGF/MET may be a significant risk factor for lymphedema. Thus, HGF may 
also become a potent therapeutic target for the treatment of lymphedema (Finegold et al., 
2008). 
Another potential new target for lymphedema therapy is matrix metalloproteinase (MMP)-
9. Sustained swelling induced by lymphatic ligation leads to lymphatic hyperplasia and 
VEGF-C upregulation; however, mice lacking MMP-9 have a larger increase in tail volume 
with secondary lymphedema as compared to wild-type mice (Rutkowski et al., 2006). 
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G-protein-coupled receptors are expressed during lymphatic development and function, 
and thus, these molecules are also potential targets for pharmacological treatment. 
Genetically engineered mouse models deficient in specific G-protein-coupled receptors have 
been used to identify several specific G-proteins, such as the adrenomedullin receptor, that 
are important for lymphatic vascular development and function (Dunworth & Caron, 2009). 
Radiation therapy, infections, or extensive surgical resection promote scarring and fibrosis 
and are, thus, also risk factors for lymphedema. Based on this finding, Avraham et al. 
examined the specific impact of fibrosis, defined as the excessive deposition of extracellular 
matrix products, on the abnormal regeneration of lymphatic vessels. Inhibition of fibrosis 
via treatment of the mouse tails with collagen type 1 gel and a moist dressing accelerated 
lymphatic regeneration and reduced post-surgical acute lymphedema in this animal model. 
Lymphatic endothelial cell proliferation was also enhanced and lymphatic function was 
improved. These results were independent of VEGF-C expression (Avraham et al., 2009). 
After discovering that fibrosis impairs lymphatic regeneration and function (Avraham et al., 
2009), Avraham et al. then searched for factors that modulate fibrosis in lymphedemous 
tissue. Transforming growth factor (TGF)-┚ is a well-known regulator of extracellular matrix 
synthesis. Inhibition of TGF-┚ causes both decreased fibrosis in virtually every organ system 
and increased lymphatic endothelial cell proliferation, migration, and tubule formation. To 
study the role of TGF-┚, the investigators compared biopsies from lymphedemous limbs of 
patients to biopsies of the normal contralateral limb. The limbs with lymphedema exhibited 
a 3-fold increase in the number of TGF-┚1-positive cells as compared to the normal limbs. 
Similarly, a mouse tail model of lymphedema was studied to determine the effect of anti-
TGF-┚1 treatment on lymphedema. Application of a TGF-┚1 antibody (TGFmab) induced a 
50-60% decrease in tail volume (a surrogate measurement for lymphedema) in treated mice 
compared to control mice. The treatment was well tolerated with no evidence of toxicity or 
wound healing complications. In the future, blockage of TGF-┚ may lead to further 
therapeutic options for augmentation of lymphatic regeneration. (Avraham et al., 2010). 
Lymphedema has also been found to arise from destructive tissue injury independent of 
lymph stasis. Based on this observation, inflammatory mediators such as tumor necrosis factor 
(TNF)-┙ and cyclooxygenase (COX) have also come under recent scrutiny. TNF-┙ is 
prominently expressed in lymphedematous tissue in mouse models and is a known inducer of 
VEGF-C expression. In a mouse tail model of lymphedema, Nakamura et al. examined the 
anti-inflammatory and possible lymphangiogenic potential of a non-steroidal anti-
inflammatory drug (NSAID) and a modified soluble form of a TNF-┙ receptor R1 (sTNF-R1) 
on TNF-┙ expression. Subcutaneous injections of the NSAID ketoprofen, which reduces 
inflammation by inhibiting COX but increases TNF-┙ levels, resulted in marked improvement 
in inflammation, normalization of histological changes, and disappearance of dilated 
microlymphatics with associated up-regulation TNF-┙ expression. Treatment with the NSAID 
also led to upregulation of VEGF-C, VEGFR-3, and Prox1, all factors associated with 
lymphangiogenesis. Treatment of mice with sTNF-R1, which directly inactivates TNF-┙ and 
downregulates its expression, did not result in improvement in lymphedema, and epidermal 
thickness actually increased in treated mice compared to untreated mice. In these treated mice, 
both VEGF-C and VEGFR-3 expression decreased as well. Though more evidence is needed, 
TNF-┙ activity and its downstream effects on VEGF-C may actually be a protective response to 
injury-induced lymphedema (Nakamura et al., 2009). 
www.intechopen.com
 Strategies in Modulating Lymphedema 
 
19 
In contrast, another study revealed that increased COX-2 expression was associated with 
recurrence of lymph flow in wound granulation tissues and with increased formation of 
lymphatic vessel endothelial hyaluronan receptor 1 (LYVE-1)-positive lymphatic-like 
structures. The authors suggest that these results differed from those of Nakamura et al. as a 
result of the important selectivity of the COX inhibitors (Kashiwagi et al., 2011). Thus, the 
role of inflammatory mediators, such as TNF-┙ and COX-2, in the treatment of lymphedema 
remains both complex and controversial. 
4. Larger animal models 
Most animal models of lymphedema are mouse models due to the practicalities of 
establishing new treatment methods; however, utilizing mice carries significant limitations. 
The microlymphatics in the superficial dermis of mouse tails and the complex 
macrostructure of human lymphatics, which includes both larger collecting vessels and 
lymph nodes, have notable differences that preclude direct correlation. Extrapolation of the 
therapeutic successes achieved in mice to humans, therefore, is dangerous without further 
experimentation in larger animals.  
To that end, Lahteenvuo et al. recently investigated the benefits of adenoviral vector-
assisted VEGF-C gene therapy in the treatment of lymphedema in pigs. Lymphedema was 
induced in pigs by excising a 3 cm piece of the inguinal lymphatic vessels that drain 
distally and proximally from the inguinal lymph node.  The pedicular lymph node was 
then reattached to the remaining tissue 4 cm laterally from its original position, thereby 
mimicking lymph node transfer in human patients. Adenoviral vectors encoding full-
length VEGF-C were then injected into the lymph node. Following injection, expression of 
VEGF-C was significantly increased. Furthermore, survival and functionality of the 
transferred lymph nodes was markedly improved in the injected animals as compared to 
the controls. Lymph node transfer has been used in humans with limited success (22-
31%), but in this model, the presence of VEGF-C resulted in better lymphatic vessel 
function, collecting vessel formation, and lymph node histology compared to controls 
(Lahteenvuo et al., 2011). 
Similar studies have also been performed on other large animals such as sheep. Using such a 
model, Baker et al. tested the effect of lymphangiogenic growth factors delivered via slow-
release diffusion on the resolution of lymphedema after lymph node extraction. A single 
popliteal lymph node was extracted from the sheep to induce distal limb lymphedema. 
Hydrogel HAMC (a blend of hyaluronan and methylcellulose that facilitates slow protein 
diffusion) infused with VEGF-C and angiopoietin-2 was then injected into the excision site. 
The animals that received treatment displayed significantly reduced edema compared with 
the untreated animals (Baker et al.). 
Though no formal testing of targeted therapies for lymphedema has been performed in 
humans to date, a few isolated case reports have been published. Sorafenib, a synthetic 
compound produced to block the enzyme RAF-kinase, was found to cause a dramatic 
reduction in chronic lymphedema in one human case study. As part of a clinical study, 
the patient took 400 mg of sorafenib twice daily, and the lymphedema was dramatically 
reduced within a few days of starting treatment. The effect was directly proportional to 
the dose and was not sustained when the drug was discontinued due to other side 
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effects. The authors hypothesized that the reduction of lymphedema was due to VEGFR-
2 blockade, which reduced vascular permeability but did not affect the VEGFR-3 
pathway involved in the proliferation of lymphatic endothelial cells (Moncrieff et al., 
2008). 
5. Limitations 
Though research into targeted therapies for lymphedema is progressing rapidly, 
significant work is still required. As stated above, there are a number of limitations with 
the animal models that are currently available. First, the models are based on acute 
lymphatic damage and not on chronic lymphedema. Lymphedema in humans is slowly 
progressive and does not recover naturally, whereas the models that are studied progress 
quickly and often regress naturally. Rats, for example, heal very quickly, and tail 
lymphedema heals itself. In fact, one of the problems in studying lymphedema treatment 
strategies is the difficulty in developing a method to sustain lymphedema long enough to 
study the outcomes of the therapies (Yoon et al., 2003). In addition, the hydrostatic 
conditions of humans differ from those of small animals, such as mice, rats, and rabbits, 
that are usually used to study lymphedema. The absolute lymphatic area damaged in 
humans is greater than in these small animals, and the regenerating lymphatic vessels 
must span a longer distance. Models using pigs, which are closer in size to humans, will 
likely be useful in addressing some of these issues. Another major concern is that VEGF-C 
and VEGFR-3 are known to promote metastasis. Since a large portion of lymphedema 
patients are breast cancer survivors, an understanding of the metastatic risks associated 
with VEGF-C treatment of lymphedema is of paramount importance. However, these 
potentially damaging side effects of VEGF-C treatment are difficult to study in animal 
models. 
6. Conclusion   
Lymphangiogenesis is a complex process that involves the interplay of many molecules 
with redundant mechanisms. VEGF-C and VEGFR-3 are known to be the primary players, 
but these molecules work in sync with other factors. Currently, no specific molecular 
treatment options are available for clinical use; however, promising results from animal 
trials suggest a role for VEGF-C gene therapy in treatment of lymphedema. Other results 
indicate that other factors such as COX-2, MMP-9, and interstitial flow dynamics may also 
be important in future management of lymphedema. Combination therapies such as stem 
cell implantation, skin grafting, and lymph node transfer in conjunction with VEGF-C 
therapy may further expand the effectiveness of future therapies as well. Design of a drug 
to treat lymphedema will require an effective animal model that accurately mimics 
lymphedema in humans. And further evaluation of the metastatic risk of inducing 
lymphangiogenesis in cancer patients is also needed. However, dramatic progress has 
been made towards effective targeted molecular therapies for lymphedema. Due to the 
proliferative efforts of researchers over the last decade, effective treatments for 
lymphedema in humans may soon be a reality. However, though a solid body of evidence 
now exists in support of targeted therapies for lymphedema, significant research is 
ultimately still needed.  
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